Sofiniclin (ABT 894) is an agonist of nicotinic acetylcholine receptor (nAChR). It is used for the research for attention-deficit/hyperactivity disorder (ADHD).

Sofiniclin is more potent than ABT-089 at both receptor subtypes, with Ki values of 1.3 nM for 125I-epibatidine binding and of 1.9 nM for 125I-α-conotoxinMII binding [1].

Compared to vehicle monkey, Sofiniclin (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs [1]. Sofiniclin (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage [2].

799279-80-4

C10H11Cl2N3

244.12

ABT 894;Sofiniclin

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years